Cardiovascular Disease
Cardiovascular Disease - Related Videos
01:27
Psychoneuroimmunology: Cardiovascular Disease
0 Views •
2025
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases. A key area of focus in PNI is the relationship between stress and coronary...
09:09
In Silico Clinical Trials for Cardiovascular Disease
0 Views •
Cited by 3 •
2022
This protocol demonstrates the workflow of the SILICOFCM platform for automatically generating a parametric model of the left ventricle from patient-specific ultrasound images by applying a multi-scale electromechanical model of the heart. This platform enables in silico clinical trials intended to reduce real clinical trials and maximize positive therapeutic outcomes.
07:25
Isolation and Excision of Murine Aorta; A Versatile Technique in the Study of Cardiovascular Disease
0 Views •
Cited by 19 •
2014
Pathology of the aorta can lead to severe morbidity and mortality, therefore research of disease progression and potential therapies is warranted. Here, we present a protocol to isolate and excise the murine aorta to aid researchers in their investigation of cardiovascular disease.
10:53
Dissection Techniques and Histological Sampling of the Heart in Large Animal Models for Cardiovascular Diseases
0 Views •
Cited by 5 •
2022
Due to the complex anatomy, a consistently reproducible dissection and harvesting protocol for cardiac samples can be challenging to implement. This manuscript presents the key elements of some standard cardiac dissection protocols, highlighting both the gross examination approaches and the sampling sites commonly used for histopathologic examination.
04:41
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
0 Views •
Cited by 7 •
2018
Circulating microRNAs have shown promise as biomarkers for cardiovascular diseases and acute myocardial infarctions. In this study, we describe a protocol for miRNA extraction, reverse transcription, and digital PCR for the absolute quantification of miRNAs in the serum of patients with cardiovascular disease.
FAQs
Statins target abnormal lipid levels, an important contributor to atherosclerotic plaque formation. By acting on this pharmacologic target, they support prevention and risk reduction rather than directly correcting every mechanism involved in cardiovascular disease. Their role is especially relevant when plaque development contributes to coronary artery disease or other vascular complications.
Vascular tone influences how constricted or relaxed blood vessels are, making it relevant to blood pressure control. Antihypertensive medicines target this aspect of cardiovascular physiology to reduce elevated pressure and its associated risks. This mechanism complements therapies directed at lipids, thrombosis, or fluid balance, allowing treatment to address different contributors to disease.
Diuretics target fluid balance, which is important when cardiovascular disease is associated with reduced cardiac pumping function. By addressing excess fluid as a treatment objective, these medicines can contribute to symptom control and broader management. Their pharmacologic role differs from agents that primarily target blood pressure, lipid levels, or clot formation.
Cardiovascular disease can arise through interacting processes, including plaque formation, inflammation, impaired vascular tone, thrombosis, and reduced cardiac pumping function. A therapy directed at one process may not address the others. Pharmacology therefore uses distinct treatment categories, such as statins, antihypertensives, antiplatelet agents, anticoagulants, and diuretics, to match different mechanistic problems.
Treatment selection begins by identifying the dominant clinical problem and its relevant mechanism. Lipid-related plaque formation may call for lipid-targeting therapy, elevated pressure for antihypertensive treatment, clot-related risk for antiplatelet or anticoagulant therapy, and fluid imbalance for diuretics. This mechanism-based approach supports prevention, symptom control, and risk reduction across several cardiovascular disorders.
Cardiovascular medicines can be evaluated by the problem they are intended to modify: lipid levels, blood pressure, clot formation, fluid balance, symptoms, or overall risk. These targets connect pharmacologic action with clinical purpose. Tracking them helps clarify whether treatment is addressing the relevant disease mechanism and supports the development of safer, more effective therapies.